$18.14 1.68 (+10.21%)
11/6/2009 4:00 PM

XenoPort, Inc. (XNPT)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.

Current Price $18.14 Mkt Cap $550.37M
Open $0.00 P/E Ratio 47.05
Prev. Close $16.46 Div. (Yield) N/A (N/A)
Daily Range $16.05 - $18.55 Volume 1,018,739
52-Wk Range $13.36 - $40.16 Avg. Daily Vol. 314,000

XNPT News and Commentary

Related News and Articles

Caps

How do you think XNPT will perform vs the S&P 500?

Add Stock to Watchlist

All Members

70 Outperform
29 Underperform
 

All-Star Members

11 Outperform
11 Underperform
 

Wall Street

11 Outperform
0 Underperform
 

Top XNPT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

majakblue (< 20)
Submitted April 26, 2007

They have a product in phase III trials. Stock will keep going up until product goes kapluuie or executives start buying castles. Pull out of this one if there is a negative report on the product!

goldminingXpert (99.98)
Submitted November 07, 2008

zeroport? As in, zero $ left in your portfolio? Truth in advertising!

XNPT VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about XNPT.

Recs

0
Member Avatar Alex1963 (97.73) Submitted: 9/17/2009 1:18:45 PM : Outperform Start Price: $24.50 XNPT Score: -26.77

from article in Morn* 9/17/09
announced positive results Thursday from a Phase IIb clinical trial for XP13512 for neuropathic pain associated with post-herpetic neuralgia. The drug candidate was successful in demonstrating statistically significant results over placebo at all dosing levels, and we plan to slightly raise our fair value estimate in the wake of this news. The 14-week, double-blind trial evaluated the safety and efficacy of XP13512 and had a total enrollment of 375 subjects with PHN who experienced pain following the healing of the herpes zoster (shingles) skin rash for at least three months. XP13512 was statistically significan t on the primary endpoint of the trial, which was improvement from baseline in the 24-hour average pain intensity score. We think this is great news for XenoPort, which experienced a setback with XP13512 in April, when the drug failed a Phase II study for pain associated with diabetes. XenoPort has partnered with GlaxoSmithKline GSK on the drug, which is still on track for final approval from the Food and Drug Administration for restless leg syndrome, having met all primary goals in its Phase III trials.

Recs

0
Member Avatar streetguru (58.30) Submitted: 1/25/2009 11:03:18 AM : Outperform Start Price: $24.24 XNPT Score: -55.59

This is a winner. FDA had some formating issues with Solzira data. Eventually this drug will pass. Target 55

Recs

0
Member Avatar TMFBiologyFool (93.06) Submitted: 11/10/2008 11:00:30 AM : Outperform Start Price: $34.50 XNPT Score: -65.02

Purely a value play. Doesn't deserve a 13% drop because Solzira's NDA has to be reformatted.

Leaderboard

Find the members with the highest scoring picks in XNPT.

Score Leader

TrackLazardCapit

TrackLazardCapit (< 20) Score: +73.95

The Score Leader is the member with the highest score across all their picks in XNPT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
Drmomski 61.99 11/17/2008 Underperform 1Y $33.12 -45.23% +27.40% +72.63
SidBord < 20 11/11/2008 Underperform 3Y $34.14 -46.87% +20.98% +67.84
pdxlucky 64.26 10/14/2008 Underperform 5Y $40.93 -55.68% +11.32% +67.00
thegraveyard < 20 2/24/2009 Underperform NS $22.53 -19.49% +44.03% +63.51
qubit15 24.89 1/21/2009 Underperform NS $24.97 -27.35% +33.85% +61.21
mukwonago53149 81.36 1/17/2008 Underperform 3Y $61.40 -70.46% -18.98% +51.47 1 Comment
drakitin 99.38 8/15/2008 Underperform 1Y $50.59 -64.14% -15.06% +49.08
Evad005 56.23 3/25/2009 Underperform 3M $21.07 -13.91% +33.11% +47.02
APGalatia 93.47 8/12/2008 Underperform 1Y $46.47 -60.96% -14.32% +46.65
RenwayGlobal 84.95 3/27/2009 Underperform 5Y $20.90 -13.21% +31.88% +45.08

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackLadenburg 46.65 6/11/2009 Outperform NS $21.66 -16.25% +14.45% -30.70
TrackMaximGroup < 20 4/28/2009 Outperform NS $14.78 +22.73% +26.17% -3.44
TrackWedbush < 20 3/20/2009 Outperform NS $19.76 -8.20% +39.62% -47.81
TrackHapoalim 51.20 2/19/2009 Outperform NS $26.02 -30.28% +36.68% -66.96
TrackPiperJaff 80.38 12/16/2008 Outperform NS $20.23 -10.33% +24.47% -34.80
TrackCreditSuiss 91.16 12/15/2008 Outperform NS $20.37 +25.38% -6.46% +31.84 2/13/2009 @ $25.54
TrackRodmanRen < 20 12/2/2008 Outperform NS $18.60 -2.47% +29.39% -31.86
TrackLazardCapit < 20 9/23/2008 Outperform NS $45.52 -67.75% -26.99% -40.76 4/27/2009 @ $14.68
TrackFBRCapitalM 75.98 7/9/2008 Outperform NS $39.35 -4.75% -1.73% -3.03 7/10/2008 @ $37.48
TrackLadenburg 46.65 5/8/2008 Outperform NS $40.00 -62.02% -36.94% -25.09 4/27/2009 @ $15.19
TrackRWBaird 85.02 4/3/2008 Outperform NS $42.92 -57.74% -18.31% -39.42
TrackRBCCapMkts 81.74 1/16/2008 Outperform NS $61.30 -70.41% -18.83% -51.58
TrackCowenandCo 74.62 9/4/2007 Outperform NS $41.43 -56.22% -23.52% -32.70
TrackCitigroup 21.22 8/9/2007 Outperform NS $42.63 -57.78% -43.04% -14.74 12/3/2008 @ $18.00
TrackDeutscheSec 89.50 4/26/2007 Outperform NS $44.64 -59.36% -24.22% -35.15
TrackFBRCapitalM 75.98 4/11/2007 Outperform NS $29.27 +72.53% +2.08% +70.45 12/3/2007 @ $50.50
TrackPZK < 20 1/17/2007 Outperform NS $24.94 -27.27% -20.40% -6.86
TrackLazardCapit < 20 8/11/2006 Outperform NS $17.82 +132.77% +18.06% +114.71 8/9/2007 @ $41.48

Featured Broker Partners